(Q45387290)

English

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys

scientific article published on 13 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys (English)

1 reference

Europe PubMed Central

14 December 2017

influenza A virus

object named as

influenza A virus

1 reference

based on heuristic

inferred from title

author name string

Tong-Ming Fu

1

1 reference

Europe PubMed Central

14 December 2017

Karen M Grimm

2

1 reference

Europe PubMed Central

14 December 2017

Michael P Citron

3

1 reference

Europe PubMed Central

14 December 2017

Daniel C Freed

4

1 reference

Europe PubMed Central

14 December 2017

Jiang Fan

5

1 reference

Europe PubMed Central

14 December 2017

Paul M Keller

6

1 reference

Europe PubMed Central

14 December 2017

John W Shiver

7

1 reference

Europe PubMed Central

14 December 2017

Xiaoping Liang

8

1 reference

Europe PubMed Central

14 December 2017

Joseph G Joyce

9

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

13 January 2009

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

27

1 reference

Europe PubMed Central

14 December 2017

9

1 reference

Europe PubMed Central

14 December 2017

1440-1447

1 reference

Europe PubMed Central

14 December 2017

Prevention and treatment of influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Global epidemiology of influenza: past and present.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

The active oligomeric state of the minimalistic influenza virus M2 ion channel is a tetramer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Viral ion channels: structure and function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Regulation of pH by the M2 protein of influenza A viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

The ion channel activity of the influenza virus M2 protein affects transport through the Golgi apparatus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

N-terminus of M2 protein could induce antibodies with inhibitory activity against influenza virus replication.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Hepatitis B virus capsid: localization of the putative immunodominant loop (residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Unusually high-level expression of a foreign gene (hepatitis B virus core antigen) in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Transformation of yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Purification of the recombinant hepatitis B virus core antigen (rHBcAg) produced in the yeast Saccharomyces cerevisiae and comparative observation of its particles by transmission electron microscopy (TEM) and atomic force microscopy (AFM).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

A simplified method for determination of peptide-protein molar ratios using amino acid analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

HBV core particles as a carrier for B cell/T cell epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Purification of recombinant HBc antigen expressed in Escherichia coli and Pichia pastoris: comparison of size-exclusion chromatography and ultracentrifugation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Folding and assembly of hepatitis B virus core protein: a new model proposal

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

The crystal structure of the human hepatitis B virus capsid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Antibody response to the M2 protein of influenza A virus expressed in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Vaccine prevention of meningococcal disease, coming soon?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

The role of B/T costimulatory signals in the immunopotentiating activity of neisserial porin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Role of B cells in antigen presentation of the hepatitis B core

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Universal influenza A vaccine: optimization of M2-based constructs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.12.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2008.12.034

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45387290&oldid=2076318191"